Diagnosis according to world health organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

Hematology

Volumn 18, Issue 1, 2013, Pages 8-13

  Ejerblad, Elisabeth ^a   Kvasnicka, Hans M ^b   Thiele, Jürgen ^b   Andreasson, Björn ^c   Björkholm, Magnus ^d   Löfvenberg, Eva ^e   Markevärn, Berit ^f   Merup, Mats ^e   Nilssson, Lars ^g   Palmblad, Jan ^e   Samuelsson, Jan ^h   Birgegård, Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF COLOGNE   (Germany)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Anagrelide; Essential thrombocythemia; Myeloproliferative neoplasm; Polycythemia vera; Primary myelofibrosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; LACTATE DEHYDROGENASE; THALIDOMIDE; TIOGUANINE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CENTRAL RETINA VEIN THROMBOSIS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; WORLD HEALTH ORGANIZATION;

EID: 84873515382     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000023     Document Type: Article

References (30)

1. Jaffe ES, Harris N, Stein H, Vardiman JW, editors. World Health Organization classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179-84.
3. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32:362-71.
4. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82: 148-52.
5. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27:2991-9.
6. Swerdlow SH, Campo E, Harris N, Jaffe ES, Pileri SA, et al., editors. WHO classification of tumours of haematopoietic and lymhoid tissues. Lyon, France: IARC press; 2008.
7. Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710-8.
8. Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758-67.
9. Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360-5; Reply, Haematologica. 2012;97:e7-8.
10. Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360-5; Comment, Haematologica. 2012;97:e5-6.
11. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60-70.
12. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in highrisk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
13. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol. 1998;61:71-6.
14. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer. 2004;101:2239-46.
15. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica. 2004;89:1306-13.
16. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863-6.
17. Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica. 2004;89:520-7.
18. Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma. 1996;22(Suppl. 1):41-5.
19. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Green AR, et al. A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematol Am Soc Hematol Educ Program. 2000;1:51-68.
20. Thiele J, Kvasnicka HM. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features-a clinicopathological study on 272 patients. Histol Histopathol. 2003;18:93-102.
21. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-32.
22. Florena AM, Tripodo C, Iannitto E, Iannitto E, Porcasi R, Ingrao S, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica. 2004;89:911-9.
23. Gianelli U, Vener C, Raviele PR, Moro A, Savi F, Annaloro C, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma. 2006;47:1774-81.
24. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137-43.
25. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-66.
26. Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218-23.
27. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270-6.
28. Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645-51.
29. Hultdin M, Sundstrom G, Wahlin A, Lundstrom B, Samuelsson J, Birgegard G, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007;24:63-70.
30. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857-9.